Associated tags: Hospital, McKesson Corporation, Pharmacy, Information technology, Patient, Managed Care, Finance, Health, Hospitals, Health Technology, Professional Services, Other Health, Insurance, Biometrics, Data Management, Cardiology, Other Professional Services, Clinical Trials, Fintech, Office of Inspector General, U.S. Department of Health and Human Services, Software, REMS, Lightning, Workflow
Locations: NEW YORK, GEORGIA, PENNSYLVANIA, UNITED STATES, NORTH AMERICA, INDIANA, CALIFORNIA
Other Professional Services,
Managed Care,
Finance,
Health,
Hospitals,
Health Technology,
Professional Services,
Other Health,
Komodo,
JPMorgan Chase,
Harvard Kennedy School,
Public policy,
McKesson Corporation,
Medidata Solutions,
Investment,
Optum,
UBS,
Management McKesson Ventures’ managing director Dave Schulte has been recognized by GrowthCap as one of the top 25 healthcare investors for 2023.
Key Points:
- McKesson Ventures’ managing director Dave Schulte has been recognized by GrowthCap as one of the top 25 healthcare investors for 2023.
- For two decades, Schulte has been investing in innovative healthcare technology and services businesses focused on improving data insights, health outcomes, and access to care.
- Schulte joined McKesson Ventures in 2014 as a managing director after 10 years leading Kaiser Permanente Ventures.
- “This recognition underscores the success of our fund and appreciation for the value of partnering with McKesson Ventures,” Schulte said.
Professional Services,
Telemedicine,
Virtual Medicine,
Health Technology,
Public Policy,
Government,
Health Insurance,
Other Science,
Healthcare Reform,
Science,
Stem Cells,
Apps,
Applications,
Practice Management,
Medical Supplies,
Other Health,
Managed Care,
Radiology,
General Health,
Pharmaceutical,
Oncology,
Other Technology,
Hospitals,
Software,
Fintech,
Clinical Trials,
Cardiology,
Data Management,
Technology,
Health,
Biometrics,
Insurance,
Finance,
REMS,
Office of Inspector General, U.S. Department of Health and Human Services,
Workflow,
McKesson Corporation,
Human services,
Pharmacy,
Lightning,
Risk Evaluation and Mitigation Strategies,
Patient,
EHR,
Ecosystem,
Pharmaceutical industry,
Nursing,
Novartis RxLightning , creator of the industry’s first comprehensive platform for streamlining specialty medication access and affordability, today announced that it closed a $17.5 million Series A investment to support the company’s growth and further remove barriers to life-saving therapies.
Key Points:
- RxLightning , creator of the industry’s first comprehensive platform for streamlining specialty medication access and affordability, today announced that it closed a $17.5 million Series A investment to support the company’s growth and further remove barriers to life-saving therapies.
- With RxLightning, healthcare providers – from those practicing at independent clinics to large health systems – leverage a streamlined workflow to complete the multi-step specialty medication onboarding process in a matter of minutes.
- RxLightning is the single destination to enroll patients for any specialty medication – brand or generic – at any specialty pharmacy.
- With RxLightning, providers and patients can complete the entire onboarding process in minutes or hours rather than days or weeks.
Retrieved on:
Thursday, December 3, 2020
Software,
Research,
Mobile,
Wireless,
Pharmaceutical,
Data management,
Oncology,
Technology,
Infectious diseases,
Clinical trials,
Science,
Biotechnology,
FDA,
Health,
Health sciences,
McKesson Corporation,
Health,
Clinical research,
EPRO,
Clinical,
Clinical Ink,
McKesson Ventures Clinical Ink , a global clinical trial technology company, today announced an investment from McKesson Ventures alongside its significantly enhanced electronic patient reported outcome (ePRO) module.
Key Points:
- Clinical Ink , a global clinical trial technology company, today announced an investment from McKesson Ventures alongside its significantly enhanced electronic patient reported outcome (ePRO) module.
- McKesson Ventures is excited to invest in Clinical Ink, a market leader in clinical trial enablement technology.
- Clinical Inks innovative eSource solutions are particularly well-positioned as the industry shifts to more decentralized trials and remote monitoring, said Dave Schulte , senior vice president and managing director of McKesson Ventures.
- McKesson Ventures is a strategic venture firm backed by McKesson Corporation focusing on early and growth stage health technology and healthcare services companies.
The Series B financing will enable Oncology Analytics to expand its oncology benefits management capabilities and accelerate strategic investments in data analytics, data science, and innovative digital health technologies.
Key Points:
- The Series B financing will enable Oncology Analytics to expand its oncology benefits management capabilities and accelerate strategic investments in data analytics, data science, and innovative digital health technologies.
- Ph.D., Venture Partner, Oak HC/FT will join Oncology Analytics' Board of Directors.
- "Oncology Analytics has the strategy, leadership team and passion to improve the delivery of cancer care.
- Oncology Analytics, Inc. provides health plans, providers and patients with an evidence-based, technology-driven approach to utilization management, which is purpose-built for oncology.
Pharmapacks sells both direct-to-consumer through leading online marketplaces including Amazon, Walmart.com, and eBay among others, as well as on Pharmapacks.com.
Key Points:
- Pharmapacks sells both direct-to-consumer through leading online marketplaces including Amazon, Walmart.com, and eBay among others, as well as on Pharmapacks.com.
- "We are excited to see Pharmapacks growing at a rapid pace, especially in an ecosystem monopolized by big e-commerce players," said Andrew Vagenas, CEO of Pharmapacks.
- Pharmapacks will use the funding to grow its 350 person team by 20 percent and scale its current 140,000 square foot warehouse in Islandia, New York.
- "We believe that this partnership will help both companies serve our online shoppers better and grow at an even faster pace."
